Law360, New York (May 9, 2006, 12:00 AM EDT) -- In a move signifying a boon for Amgen Inc. and a threat to the proposed sales of Hoffman-La Roche Inc.'s anti-anemia drug C.E.R.A. in the U.S., the U.S. International Trade Commission has initiated an investigation into whether the U.S. importation and sale of C.E.R.A. would violate Amgen’s patent rights.
C.E.R.A. violates six of Amgen’s U.S. patents, according to a press release issued by Amgen.
Roche fired back Tuesday in a statement of its own, painting Amgen as an anti-competitive company seeking to muscle out a rival....
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.